Ozempic vs ZepboundOzempic vs Zepbound — semaglutide (diabetes indication) vs tirzepatide (obesity indication). Trial comparison and the product-indication distinction.

Short answer: Ozempic (semaglutide, diabetes indication) vs Zepbound (tirzepatide, obesity indication) — like comparing Ozempic vs Mounjaro, since Zepbound is tirzepatide's weight-management brand. Zepbound's ~20% trial weight loss exceeds Ozempic's diabetes-dose results, but they carry different approved indications.

The product-indication distinction

Zepbound is tirzepatide approved specifically for obesity — same molecule as Mounjaro (diabetes brand). This mirrors Ozempic (diabetes) vs Wegovy (weight) — same molecule, different products. The comparison is really semaglutide vs tirzepatide: tirzepatide shows superior weight loss in trials.

Ozempic (semaglutide) FDA Prescribing Information, Novo Nordisk, 2024.

STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM 2021).

SUSTAIN 6 — Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (Marso et al., NEJM 2016).

American Diabetes Association — Standards of Care in Diabetes — 2026.

NICE Guideline NG28 — Type 2 diabetes in adults: management.

World Health Organization — Diabetes fact sheet.

Browse all pages